

Julien Zuber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/833552/publications.pdf>

Version: 2024-02-01

57
papers

3,700
citations

201674

27
h-index

144013

57
g-index

61
all docs

61
docs citations

61
times ranked

4353
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab. <i>American Journal of Transplantation</i> , 2022, 22, 2099-2103.	4.7	14
2	Editorial: Immunogenomics of Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2022, 13, 878314.	4.8	0
3	Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection. <i>Kidney International</i> , 2022, 101, 1290-1293.	5.2	25
4	COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. <i>American Journal of Transplantation</i> , 2021, 21, 1285-1294.	4.7	69
5	Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. <i>American Journal of Transplantation</i> , 2021, 21, 2448-2458.	4.7	31
6	Time-dependent lymphocyte count after transplantation is associated with higher risk of graft failure and death. <i>Kidney International</i> , 2021, 99, 1189-1201.	5.2	8
7	Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection. <i>Kidney International</i> , 2021, 99, 486-488.	5.2	30
8	Ig-responsive relapsing inflammatory syndrome following COVID-19 in a kidney transplant recipient. <i>Kidney International</i> , 2021, 99, 767-768.	5.2	3
9	A combination of cyclophosphamide and interleukin-2 allows CD4+ T cells converted to Tregs to control scurfy syndrome. <i>Blood</i> , 2021, 137, 2326-2336.	1.4	9
10	Lymphohematopoietic graft-versus-host responses promote mixed chimerism in patients receiving intestinal transplantation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	31
11	Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. <i>Transplantation</i> , 2021, 105, e94-e95.	1.0	105
12	Single-cell analysis of FOXP3 deficiencies in humans and mice unmasks intrinsic and extrinsic CD4+ T cell perturbations. <i>Nature Immunology</i> , 2021, 22, 607-619.	14.5	35
13	Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life. <i>Kidney International Reports</i> , 2021, 6, 1489-1491.	0.8	5
14	A DL-4- and TNF±-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1662-1676.	10.5	6
15	Chronic histiocytic intervillitis: manifestation of placental alloantibody-mediated rejection. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 662.e1-662.e11.	1.3	13
16	The Case Cardiac tamponade in a kidney transplant recipient with chronic inflammation. <i>Kidney International</i> , 2021, 100, 487-488.	5.2	0
17	Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. <i>American Journal of Transplantation</i> , 2021, 21, 4043-4051.	4.7	84
18	Immune Checkpoint Inhibitors in Transplantation—A Case Series and Comprehensive Review of Current Knowledge. <i>Transplantation</i> , 2021, 105, 67-78.	1.0	21

#	ARTICLE	IF	CITATIONS
19	Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction. <i>Nature Communications</i> , 2021, 12, 6446.	12.8	35
20	CRISPR/Cas9-Engineered HLA-Deleted Glomerular Endothelial Cells as a Tool to Predict Pathogenic Non-HLA Antibodies in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3231-3251.	6.1	8
21	Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience. <i>Transplantation</i> , 2020, 104, 2625-2631.	1.0	15
22	Donor-targeted serotherapy as a rescue therapy for steroid-resistant acute GVHD after HLA-mismatched kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 2243-2253.	4.7	11
23	Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. <i>Haematologica</i> , 2019, 104, 2501-2511.	3.5	40
24	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2449-2463.	6.1	81
25	No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained <sc>BK</sc> virus viremia after kidney transplantation: a single-center experience. <i>Transplant International</i> , 2019, 32, 481-492.	1.6	8
26	Baseline graft status is a critical predictor of kidney graft failure after diarrhoea. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1597-1604.	0.7	2
27	Human Intestinal Allografts Contain Functional Hematopoietic Stem and Progenitor Cells that Are Maintained by a Circulating Pool. <i>Cell Stem Cell</i> , 2019, 24, 227-239.e8.	11.1	43
28	Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus. <i>Transplant Infectious Disease</i> , 2018, 20, e12846.	1.7	7
29	Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. <i>JCI Insight</i> , 2018, 3, .	5.0	54
30	Quantifying size and diversity of the human T cell alloresponse. <i>JCI Insight</i> , 2018, 3, .	5.0	69
31	Haemolytic uraemic syndrome. <i>Lancet, The</i> , 2017, 390, 681-696.	13.7	397
32	Long-term Outcomes of Kidney Transplantation in Patients With High Levels of Preformed DSA. <i>Transplantation</i> , 2017, 101, 2440-2448.	1.0	60
33	<i>Cryptosporidium</i> spp. Infection in Solid Organ Transplantation. <i>Transplantation</i> , 2017, 101, 826-830.	1.0	44
34	Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. <i>Journal of Hepatology</i> , 2017, 67, 1334-1339.	3.7	32
35	Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. <i>Transplantation</i> , 2017, 101, 2924-2930.	1.0	21
36	Mechanisms of Mixed Chimerism-Based Transplant Tolerance. <i>Trends in Immunology</i> , 2017, 38, 829-843.	6.8	66

#	ARTICLE	IF	CITATIONS
37	Bidirectional intragraft alloreactivity drives the repopulation of human intestinal allografts and correlates with clinical outcome. <i>Science Immunology</i> , 2016, 1, .	11.9	98
38	Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 487-495.	0.7	23
39	De Novo Donor-Specific Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection. <i>Transplantation</i> , 2015, 99, 965-972.	1.0	28
40	Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients. <i>Science Translational Medicine</i> , 2015, 7, 272ra10.	12.4	191
41	Diarrhea After Kidney Transplantation. <i>Transplantation</i> , 2014, 98, 806-816.	1.0	55
42	Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. <i>Transplantation Reviews</i> , 2013, 27, 117-125.	2.9	74
43	Genetics and Outcome of Atypical Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 554-562.	4.5	567
44	Eculizumab in renal transplantation. <i>Transplantation Reviews</i> , 2013, 27, 90-92.	2.9	39
45	Prognostic significance of graft Foxp3 expression in renal transplant recipients: a critical review and attempt to reconcile discrepancies. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1100-1111.	0.7	20
46	Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. <i>Nature Reviews Nephrology</i> , 2012, 8, 643-657.	9.6	448
47	Clinical and immunological features of very long-term survivors with a single renal transplant. <i>Transplant International</i> , 2012, 25, 545-554.	1.6	26
48	New insights into postrenal transplant hemolytic uremic syndrome. <i>Nature Reviews Nephrology</i> , 2011, 7, 23-35.	9.6	169
49	Impact of Norovirus/Sapovirus-Related Diarrhea in Renal Transplant Recipients Hospitalized for Diarrhea. <i>Transplantation</i> , 2011, 92, 61-69.	1.0	130
50	Harnessing regulatory T cells for transplant tolerance in the clinic through mTOR inhibition. <i>Current Opinion in Organ Transplantation</i> , 2011, 16, 606-613.	1.6	10
51	Donor-Specific Antibodies Accelerate Arteriosclerosis after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 975-983.	6.1	88
52	Combined Posttransplant Prophylactic IVIg/Anti-CD 20/Plasmapheresis in Kidney Recipients With Preformed Donor-Specific Antibodies: A Pilot Study. <i>Transplantation</i> , 2010, 89, 1403-1410.	1.0	133
53	Glomerular Collapse Associated With Subtotal Renal Infarction in Kidney Transplant Recipients With Multiple Renal Arteries. <i>American Journal of Kidney Diseases</i> , 2010, 55, 558-565.	1.9	22
54	HNF1B-related diabetes triggered by renal transplantation. <i>Nature Reviews Nephrology</i> , 2009, 5, 480-484.	9.6	18

#	ARTICLE	IF	CITATIONS
55	High-Dosage Intravenous Immunoglobulinâ€™Associated Macrovacuoles Are Associated with Chronic Tubulointerstitial Lesion Worsening in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1461-1468.	4.5	14
56	Long-term outcome of third kidney transplants. Nephrology Dialysis Transplantation, 2007, 22, 2693-2700.	0.7	34
57	Severe FOXP3+ and Naïve T Lymphopenia in a Non-IPEX Form of Autoimmune Enteropathy Combined With an Immunodeficiency. Gastroenterology, 2007, 132, 1694-1704.	1.3	26